- Home
- MCRB vs COCH Comparison
MCRB vs COCH Comparison
Compare MCRB & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCRB | COCH |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 51.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCRB | COCH |
|---|---|---|
| Price | $4.68 | $0.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $6.00 |
| AVG Volume (30 Days) | 53.3K | ★ 154.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,000.00 | $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $4.32 | $0.36 |
| 52 Week High | $29.98 | $1.89 |
Technical Indicators
Market Signals| Indicator | MCRB | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 56.12 |
| Support Level | N/A | $0.63 |
| Resistance Level | $5.65 | $0.88 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 10.86 | 60.90 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.